Company / Current Assets
Akebia Therapeutics, Inc. Current Assets History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$253.0M
FY2025
5-year range
$113.8M / $272.0M
FY2021-FY2025
Trend
+122.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2025 after 4 years of decline, reaching $253M.
Based on SEC 10-K filings.
$253M in FY2025 with a 10-year CAGR of +6.0%.
Improved from $118M to $253M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +11.0%
- 5-Year CAGR
- -7.4%
- 10-Year CAGR
- +6.0%
Key checks
Key Insights
- 5-year CAGR of -7.4%, indicating a declining trend.
- In FY2025, current assets increased 122.2% year-over-year.
- Peak current assets was recorded in FY2018.
- Lowest current assets in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $253.0M | +122.2% |
| FY2024 | $113.8M | -3.7% |
| FY2023 | $118.1M | -36.2% |
| FY2022 | $185.2M | -31.9% |
| FY2021 | $272.0M | -26.8% |
| FY2020 | $371.4M | +20.0% |
| FY2019 | $309.5M | -33.9% |
| FY2018 | $468.3M | +232.1% |
| FY2015 | $141.0M | +27.6% |
| FY2014 | $110.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026